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Gaucher disease is caused by mutations in the glucocerebrosidase gene, which encodes the lysosomal hydrolase glucosylcer-
amidase. Patients with Gaucher disease and heterozygous glucocerebrosidase mutation carriers are at increased risk of develop-
ing Parkinson’s disease. Indeed, glucocerebrosidase mutations are the most frequent risk factor for Parkinson’s disease in the
general population. Therefore there is an urgent need to understand the mechanisms by which glucocerebrosidase mutations
predispose to neurodegeneration to facilitate development of novel treatments. To study this we generated fibroblast lines from
skin biopsies of five patients with Gaucher disease and six heterozygous glucocerebrosidase mutation carriers with and without
Parkinson’s disease. Glucosylceramidase protein and enzyme activity levels were assayed. Oxidative stress was assayed by
single cell imaging of dihydroethidium. Glucosylceramidase enzyme activity was significantly reduced in fibroblasts from
patients with Gaucher disease (median 5% of controls, P = 0.0001) and heterozygous mutation carriers with (median 59% of
controls, P = 0.001) and without (56% of controls, P = 0.001) Parkinson’s disease compared with controls. Glucosylceramidase
protein levels, assessed by western blot, were significantly reduced in fibroblasts from Gaucher disease (median glucosylcer-
amidase levels 42% of control, P50.001) and heterozygous mutation carriers with (median 59% of control, P5 0.001) and
without (median 68% of control, P50.001) Parkinson’s disease. Single cell imaging of dihydroethidium demonstrated increased
production of cytosolic reactive oxygen species in fibroblasts from patients with Gaucher disease (dihydroethidium oxidation
rate increased by a median of 62% compared to controls, P5 0.001) and heterozygous mutation carriers with (dihydroethidium
oxidation rate increased by a median of 68% compared with controls, P5 0.001) and without (dihydroethidium oxidation rate
increased by a median of 70% compared with controls, P5 0.001) Parkinson’s disease. We hypothesized that treatment with
the molecular chaperone ambroxol hydrochloride would improve these biochemical abnormalities. Treatment with ambroxol
hydrochloride increased glucosylceramidase activity in fibroblasts from healthy controls, Gaucher disease and heterozygous
glucocerebrosidase mutation carriers with and without Parkinson’s disease. This was associated with a significant reduction
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in dihydroethidium oxidation rate of 50% (P50.05) in fibroblasts from controls, Gaucher disease and heterozygous mutation
carriers with and without Parkinson’s disease. In conclusion, glucocerebrosidase mutations are associated with reductions in
glucosylceramidase activity and evidence of oxidative stress. Ambroxol treatment significantly increases glucosylceramidase
activity and reduces markers of oxidative stress in cells bearing glucocerebrosidase mutations. We propose that ambroxol
hydrochloride should be further investigated as a potential treatment for Parkinson’s disease.
Keywords: Parkinson’s disease; ambroxol; lysosome; Gaucher disease; glucocerebrosidase
Abbreviation: CLEAR = coordinated lysosomal expression and regulation
Introduction
The autophagy–lysosome system plays a key role in degrading the
misfolded proteins that form the abnormal protein accumulations
that occur in the common late onset neurodegenerative diseases.
In concert with the proteasome, the autophagy–lysosome system
degrades tau, the proteins that form neurofibrillary tangles in
Alzheimer’s disease (Lee et al., 2013). Markers of dysfunctional
autophagy have been described in motor neuron disease spinal
cord (Otomo et al., 2012), and the autophagy–lysosome system
plays a role in degrading superoxide dismutase 1 and TBP43 (now
known as TARDBP) (Otomo et al., 2012). There is also strong
evidence for a role of this system in the aetiopathogenesis of
Parkinson’s disease (Goker-Alpan, et al., 2010; Ebrahimi-Fakhari
et al., 2012; Houlden et al., 2012). Accumulation of p62 and
LC3-II, markers of dysfunction of the autophagy–lysosome
system, has been described in post-mortem Parkinson’s disease
brain (Alvarez-Erviti et al., 2010; Dehay et al., 2013). In addition
cell biology studies have demonstrated that inhibition of
the autophagy–lysosome system, and in particular chaperone-
mediated autophagy, is associated with elevation of alpha-synu-
clein protein levels (Alvarez-Erviti et al., 2010). Recently,
mutations in the glucocerebrosidase gene (GBA), which encodes
the lysosomal hydrolase glucosylceramidase deficient in Gaucher
disease, have been identified as a risk factor for the development
of Parkinson’s disease (Sidransky et al., 2009; Sidransky and
Lopez, 2012), dementia with Lewy bodies (Nalls et al., 2013)
and a subtype of Alzheimer’s disease (Tsuang et al., 2012).
Three broad clinical subtypes of Gaucher disease are recognized
(Balwani et al., 2010). In type I (non-neuronopathic) Gaucher disease,
patients develop combinations of blood dyscrasia, hepato-splenomegaly
and bone disease (Balwani et al., 2010). Patients with types II (acute
neuronopathic) and III (chronic neuronopathic) Gaucher disease present
with a predominantly neurodegenerative syndrome in childhood or
early adulthood (Tajima et al., 2009). Several hundred GBA mutations
have been reported, but the most common are the N370S and L444P
missense mutations (Hruska et al., 2008). There is no precise geno-
type–phenotype correlation but patients with the N370S allele generally
develop non-neuropathic disease (Balwani et al., 2010). The clinical
manifestations of Gaucher disease are associated with lysosomal accu-
mulation of the glucosylceramidase substrates glucosylceramide and
glucosylsphingosine (Balwani et al., 2010). Patients with Gaucher
disease have an 8–12% chance of developing Parkinson’s disease by
age 80 (Rosenbloom et al., 2011) whereas the risk in heterozygous
GBA mutations carriers is 10–15% by age 80 (McNeill et al., 2012).
The mechanisms by which GBA mutations predispose to neuro-
degeneration remain unclear. However, post-mortem studies have
demonstrated severe loss of glucosylceramidase enzyme activity in
brain tissue from patients with Gaucher disease and in the
substantia nigra of patients with Parkinson’s disease (Mazzulli
et al., 2011; Gegg et al., 2012) and patients with Lewy body
dementia (Kurzawa-Akanbi et al., 2012) with and without GBA
mutations. Current evidence thus supports a central role for neur-
onal loss of glucosylceramidase activity in the pathogenesis of
neurodegeneration associated with GBA mutations. The majority
of GBA mutations do not affect the catalytic site of glucosylcer-
amidase, and so other mechanisms must account for loss of
enzyme activity in Parkinson’s disease and Gaucher disease
(Hruska et al., 2008). There is evidence that GBA missense
mutations cause endoplasmic reticulum retention and proteasomal
degradation of the mutant protein (Ron et al., 2005; Sawkar
et al., 2006). Given that there is reduction of glucosylceramidase
activity in brain tissue from patients with Parkinson’s disease and
those with Lewy body dementia, with and without GBA muta-
tions, there is clearly an urgent need to understand how reduced
glucosylceramidase activity causes neurodegeneration to facilitate
development of new treatments.
The GBA gene is part of the CLEAR network (coordinated lyso-
somal expression and regulation), which consists of 4400 genes
(Palmieri et al., 2011). The CLEAR network is regulated by tran-
scription factor EB (TFEB), which acts to induce transcriptional
upregulation of the CLEAR network in a synchronized fashion
(Song et al., 2013). The genes of the CLEAR network encode all
the proteins required for lysosomal biogenesis and function;
including the lysosomal enzymes, lysosomal membrane proteins,
autophagy molecules and proteins required for trafficking. The
CLEAR network thus represents an attractive therapeutic target
for improving function of the autophagy–lysosome system in
Parkinson’s disease. Demonstrating activation of the CLEAR net-
work can be performed by showing synchronous upregulation of
CLEAR network genes by using microarray gene expression
profiling (Palmieri et al., 2011).
Here we focused on identifying cellular biochemical changes
associated with GBA mutations that might predispose to neurode-
generation using fibroblasts generated from a series of patients
with Gaucher disease and heterozygous GBA mutation carriers
with and without Parkinson’s disease. We then reasoned that
ambroxol hydrochloride, a small molecule previously shown to
improve glucosylceramidase function in Gaucher disease
(Maegawa et al., 2009), might ameliorate the cellular phenotypes
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in Gaucher disease and GBA mutation heterozygotes. Our findings
indicate that GBA mutations are associated with oxidative and
endoplasmic reticulum stress and that ambroxol can improve lyso-
somal biochemistry in these cells by activating the CLEAR network.
We propose that these results are of relevance to the targeting of
potential novel interventions to slow the progression of
Parkinson’s disease and other GBA-related disorders.
Materials and methods
Patients and fibroblast culture
Fibroblasts were generated from skin biopsies of five patients with
type I Gaucher disease, four heterozygous carriers with Parkinson’s
disease, one patient with Parkinson’s disease with homozygous
E326K GBA mutation, two carriers without Parkinson’s disease
(non-manifesting carriers) and three patients with Parkinson’s disease
without GBA mutations. For comparison, fibroblasts were generated
from three control subjects without neurological disease or GBA
mutations. All groups were matched for age and sex. The clinical
characteristics and mutation spectrum of the patient cohort are
given in Table 1. Fibroblasts were grown in Dulbecco’s modified
Eagle medium with 4.5 g/l glucose (Invitrogen), 5% serum, 5% pyru-
vate, fungizone and penicillin–streptomycin. Fibroblasts were studied
at low passage, and disease and control were matched for passage
number.
Alpha-synuclein over expressing cell
lines
To investigate factors modulating cellular alpha-synuclein levels, an
SH-SY5Y stable cell line expressing high levels of exogenous wild-
type alpha-synuclein were used. Exogenously expressed
alpha-synuclein contains a haemagglutinin tag (HA) at the C-terminal.
All SH-SY5Y cell lines were cultured in 1:1 Dulbecco’s modified Eagle
medium/F12 (Invitrogen) supplemented with 10% foetal calf serum,
non-essential amino acids, 1 mM sodium pyruvate and penicillin–
streptomycin.
Indirect immunofluorescence
Cells were grown on coverslips, fixed in 4% paraformaldehyde for
15 min and permeabilized in ice cold methanol. Blocking was per-
formed in 2% goat serum before incubation with primary and second-
ary antibodies. Anti-glucocerebrosidase (Abcam) was used at a
concentration of 1:50 and anti-calnexin (Abcam) at 1:500.
Lysosomal enzyme assays
The glucosylceramidase enzymatic assay was performed using a
fluorometric assay with 10 mM 4-methylumbelliferyl-b-D-glucopyrano-
side (Sigma) as the substrate. Glucosylceramidase activity is reported in
the presence of the activator sodium taurocholate (Sigma). Total
beta-hexosaminidase and beta-galactosidase were assayed with
4-methylumbelliferyl-2-acetoamido-2-deoxy-6-sulpho-b-D-glucopyran-
soside and 4-methylumbelliferyl-B-D-galactopyranoside as substrates,
respectively.
Lyso-ID protocol
Cells were grown overnight in 96-well plates, three wells per cell line.
Cells were incubated for 30 min with Lyso-ID green dye (Enzo life
sciences), a cell permeable fluorescent probe which localizes to acidic
vesicles (endosomes, lysosomes, late autophagosomes). Dye was
washed off and fluorescence read on a plate reader, with results
normalized to protein content.
Table 1 Characteristics of patient-derived fibroblasts
Patient (ID, gender/age) Genotype Clinical features
Gaucher disease
GD01, M/50 N370S/c1263del55 Type I Gaucher disease
GD02, M/70 N370S/N370S Type I Gaucher disease
GD03, M/55 N370S/L444P Type I Gaucher disease
GD04, M/61 N370S/203insC Type I Gaucher disease
GD05, M/40 N370S/L444P Type I Gaucher disease
Non-manifesting carrier
C01, F/80 N370S/WT No neurological disease
C02, M/62 L444P/WT No neurological disease
Parkinson’s disease with GBA mutation
PD01, F/53 N370S/WT Parkinson’s disease
PD02, M/45 N370S/WT Parkinson’s disease
PD03, M/72 L444P/WT Parkinson’s disease
PD04, F/61 RecNcil/WT Parkinson’s disease
PD05, M/50 E326K/E326K Parkinson’s disease
Control
CN01, M/78 WT/WT No neurological disease
CN02, M/81 WT/WT No neurological disease
CN03, F/50 WT/WT No neurological disease
WT = wild-type.
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Western blotting
Fibroblasts were trypsinized and resuspended in 1 ml PBS. Each sample
was then treated with 100ml lysis buffer with protease inhibitors
(1% TritonTM X-100 with 1 mg/ml leupeptin, 1 mM PMSF, 1 mg/ml
pepstatin, 1 mM NaV). Cell lysates were then centrifuged at full
speed for 10 min and the supernatant transferred to fresh tubes.
Lysates containing 30 mg of protein were then electrophoresed on a
4–12% NuPage gel (Invitrogen). Proteins were transferred to a PVDF
membrane (Amersham), blocked in non-fat milk, treated with primary
antibody and secondary antibodies. Antibody binding was then
detected using an ECL chemiluminescence kit. The following antibo-
dies were used: glucocerebrosidase (ab55080 Abcam), actin (AC15
Abcam), LIMP2 (ab106519 Abcam), LC-3 (Cell signalling), cathepsin
D (ab40697 Abcam), anti-haemagglutin (covance HA.11) and p62
(ab56416 Abcam). For each antibody, three controls were run
alongside the patient samples on each gel. The band intensity for
the three controls was averaged and the patient results were expressed
as a percentage of the mean control value.
TFEB enzyme-linked immunosorbent
assay
The TFEB ELISA was developed and performed in-house at Signosis
Inc. Nuclear and cytosolic fractionation of fibroblasts was performed
in-house at Signosis Inc. using the SK-0001 nuclear extraction kit. The
TFEB ELISA was performed on three separate cultures from control line
3 treated with ambroxol and three separate untreated cultures from
control line 3.
Endoglycosidase-H treatment
Twenty micrograms of protein was denatured with glycoprotein dena-
turing buffer (New England Biolabs 5% SDS, 0.4 M dithiothreitol) at
100C. The lysate was then incubated for 12 h with 1 000 units of
endoglycosidase-H and reaction buffer (New England Biolabs 0.5 M
sodium citrate, pH 5.5). The lysate was then used in the western
blot protocol outlined above.
Proteasome inhibition
Sub-confluent 10-cm plates of fibroblasts were treated with
proteasome inhibitor (MG132 15 mM and ALLN 25 mM, sigma) for
18 h. This cocktail significantly inhibits PGP-like (MG132 100% and
ALLN 92% inhibition, P5 0.05), chymotrypsin (53% and 57% inhib-
ition, P5 0.05) and trypsin-like (54% and 65% inhibition, P5 0.05)
activity in neuroblastoma cells.
Ambroxol hydrochloride treatment
An initial titration experiment was performed to select the dose of
ambroxol hydrochloride to use for rescue experiments. Ambroxol
hydrochloride (Sigma) was dissolved in dimethylsulphoxide (DMSO)
and diluted in cell culture media to give a final concentration of
10 mM, 30 mM and 60 mM. This dose range was selected based upon
dosages used in previous in vitro studies (Maegawa et al., 2009; Luan
et al., 2013). In the initial titration experiment a control line and a
Gaucher disease line were treated with 10mM, 30 mM and 60mM for
5 days. Media were changed daily for ambroxol treated and control
lines. Controls were treated with DMSO only. The greatest increase in
glucosylceramidase protein levels were observed with 60 mM
(Supplementary Fig. 1), and this dose was therefore selected for the
rescue experiments.
Gene expression profiling
RNA was extracted from cultured fibroblasts (5106 cells) using the
RNeasy kit (Qiagen) and converted to complementary DNA with
QuantiTect reverse transcription kit (Qiagen). Gene expression profil-
ing was performed on complementary DNA from a single control
fibroblast line with (n = 3) and without (n = 3) ambroxol treatment
using a GeneChip Human Genome U133 Plus 2.0 Array from
Affymetrix. Control fibroblasts were used to avoid potential confound-
ing as a result of changes in gene expression potentially associated
with GBA mutations. Hybridizations and data analyses were performed
at Source Bioscience. Gene set enrichment analysis was performed as
described previously for lysosome and autophagy gene sets
(Subramanian et al., 2005). A nominal P-value 50.05 and a false
discovery rate of 52% were used to assess the statistical significance
of the enrichment score. Gene set ANOVA was performed on KEGG
pathways (lysosome, autophagy) using Partek Genomics Suite (6.5).
Relative expression of GBA, NQO1 and b-actin messenger RNA in
untreated cells was measured with Power SYBR Green kit (Applied
Biosystems) using a StepOneTM PCR machine (Applied Biosystems). To
analyse the effect of ambroxol treatment both treated and untreated
cells had TFEB, aspartyl glucosaminidase, cathepsin K, SCARB2/LIMP2,
hexosaminidase A and iduronidase alpha measured using the
TaqMan PCR system. b-actin messenger RNA levels were used to
normalise data. Relative expression was calculated using the CT
method. Details of primers are given in Supplementary Table 1.
Single cell imaging of dihydroethidium
and monochlorobimane
Cytosolic reactive oxygen species production was monitored by single
cell analysis of dihydroethidium oxidation rate. For each cell line,
fibroblasts were imaged with dihydroethidium dissolved in HEPES buf-
fered salt solution (156 mM NaCl, 3 mM KCl, 2 mM MgSO4, 1.25 mM
KH2PO4, 2 mM CaCl2, 10 mM glucose, and 10 mM HEPES, pH ad-
justed to 7.35 with NaOH). No preincubation (‘loading’) was per-
formed to minimize intracellular accumulation of the oxidized
product. The amount of dihydroethidium used in each run was deter-
mined by adjusting the concentration of dihydroethidium until it was
sufficient to ensure that cellular non-oxidized (i.e. cytoplasmic) fluor-
escence reached a peak rapidly. Fluorescence images were obtained on
an epifluorescence inverted microscope equipped with a 20 fluorite
objective (Cairn Research). For hydroethidium measurements, a ratio
of the oxidized to reduced form was measured: excitation at 530 nm
and emission recorded 4560 nm were used to quantify the oxidized
form (ethidium), whereas excitation at 360 nm and emission collected
from 405 to 470 nm was used for the reduced form (dihydroethidium).
All data reported in this study were obtained from at least five cover-
slips and two to three different cell and sample preparations.
Glutathione measurements
To measure glutathione (GSH), cells were incubated with 50mM
monochlorobimane (Molecular Probes). As monochlorobimane reacts
with GSH in a reaction catalysed by gluthatione S-transferase, gener-
ating a fluorescent adduct, cells were incubated with the dye in HEPES
balanced salt solution at room temperature for 40 min, or until a
steady state had been reached before images were acquired for
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quantitation. The cells were then washed with HEPES balanced salt
solution, and images of the fluorescence of the monochlorobimane-
GSH adduct were acquired using the LSM510 system using excitation
at 380 nm and emission at 4400 nm.
Statistical and image analysis
Densitometric analysis of western blots was performed using ImageJ
(NIH, http://rsb.info.nih.gov/ij/). Statistical analysis was performed
using PASW (IBM version 20.1). Means were compared with
Student’s t-test and medians with a Mann-Whitney U-test. Medians
were used to compare non-parametric data (percentages of protein
expression on western blot and fold change of protein and transcript
levels), means were used to compare parametric data (rates of enzyme
activity). For between-group comparisons (Gaucher disease, E326k/
E326K, Parkinson’s disease or non-manifesting carrier compared with
controls) Bonferroni correction was applied. As four comparisons were
being made for each marker significance at the 5% level was set at
P = 0.0125 (0.05/4). Bonferroni correction was not applied to com-
parisons made between cells treated with ambroxol and their
untreated control, as this was a single statistical test and multiple com-
parisons were not made. The statistical methodology for the gene
expression profiling experiments is detailed above. All experiments
were performed in biological triplicate.
Results
Glucosylceramidase activity is decreased in fibroblasts from
patients with Gaucher disease and heterozygous GBA mutation
carriers with and without Parkinson’s disease
Western blotting revealed a significant reduction in glucosylcer-
amidase protein levels in all Gaucher disease, Parkinson’s disease
with GBA mutation, E326K/E326K and non-manifesting carrier
cell lines (Fig. 1A and B). Glucosylceramidase activity (measured
in the presence of sodium taurocholate) in Gaucher disease,
Parkinson’s disease with GBA mutation and non-manifesting car-
rier lines was significantly lower than controls (Fig. 1C).
Glucosylceramidase activity in fibroblasts from the E326K homo-
zygous Parkinson’s disease case was also significantly reduced
compared with controls, at a level intermediate between
Gaucher disease, Parkinson’s disease with GBA mutation and
non-manifesting carrier. Glucosylceramidase activity in fibroblasts
from patients with sporadic Parkinson’s disease did not differ from
controls (365  30 versus 325  30 nmol/mg/h, t-test P = 0.17).
GBA transcript levels were reduced in Gaucher disease lines with
N370S/203insC (Patient GD4, median 30% of control, Mann-
Whitney U test P = 0.001), N370S/c1263del55 (Patient GD1,
median 66% of control, P = 0.007) or N370S/L444P (Patient
GD5 median 56% of control, P = 0.001) mutations and in
Parkinson’s disease with L444P (Patient PD3 median 42% of con-
trol, P = 0.001) or RecNcil (Patient PD4, 55% of control,
P = 0.007) mutations (Fig. 1). Transcript levels were not reduced
in N370S/N3270S Gaucher disease (Patient GD2), E326K homo-
zygous cells or Parkinson’s disease fibroblasts with N370S alleles
(Patients PD1 and PD2) (Fig. 1D).
LIMP2 (SCARB2) acts as a chaperone helping to traffic gluco-
sylceramidase from the endoplasmic reticulum to the lysosome. To
ensure that glucosylceramidase depletion was not secondary to
loss of LIMP2 expression western blot measurement of LIMP2
levels was performed. LIMP2 levels did not differ from controls
in either Gaucher disease {median 93% of control [interquartile
range (IQR) 90–105%], Mann-Whitney U-test P = 0.33},
Parkinson’s disease with GBA mutations [median 93% of control
(IQR 90–100%), P = 0.12] or non-manifesting carrier [median
95% (IQR 90–105%) P = 0.1] fibroblasts (data not shown).
For each cell line indirect immunofluorescence using antibodies
to glucosylceramidase and calnexin (an endoplasmic reticulum
marker) was performed. In control cells glucosylceramidase was
clearly seen to accumulate in punctate structures at the cell per-
iphery which morphologically resembled lysosomes and did not
co-localize with calnexin. The distribution of glucosylceramidase
in Parkinson’s disease with GBA mutation and non-manifesting
carrier cells was not readily distinguishable from control fibroblast
lines. However, in Gaucher disease fibroblasts there was a marked
reduction in the staining of the punctate lysosomal structures,
most of the glucosylceramidase was observed to accumulate in a
peri-nuclear pattern and co-localize with calnexin (yellow peri-
nuclear staining in cells in Fig. 2A). Endoplasmic reticulum retained
forms of glucosylceramidase carry N-linked glycans which are
sensitive to cleavage by endoglycosidase-H, producing a low
molecular weight band of glycosylceramidase on western blotting.
The endoglycosidase-H sensitive fraction of glucosylceramidase
was significantly higher in Gaucher disease, E326K/E326K,
Parkinson’s disease with GBA mutation and non-manifesting
carrier fibroblasts; indicating endoplasmic reticulum retention in
all these lines (Fig. 2B and C).
Given the reduced glucosylceramidase protein levels and evi-
dence of endoplasmic reticulum retention of glucosylceramidase
in the disease fibroblasts, we hypothesized that reduced levels
may result from proteasomal degradation. Disease and control
fibroblasts were treated with the proteasomal inhibitors MG132
and ALLN for 18 h and then harvested. Proteasome inhibition re-
sulted in elevated glucosylceramidase protein levels, as assessed by
western blotting, within Gaucher disease fibroblasts [median 49%
increase (IQR 30–62%), Mann-Whitney U-test P = 0.029] and
Parkinson’s disease with GBA mutation fibroblasts [median in-
crease 25% (IQR 15–35%), P = 0.043] to a greater degree than
in controls (median 2% increase).
GBA mutations are associated with
markers of endoplasmic reticulum and
oxidative stress in fibroblasts
Given the evidence of endoplasmic reticulum retention of gluco-
sylceramidase we assessed the cell lines for evidence of
endoplasmic reticulum stress by western blotting (Fig. 2D). There
was BiP/Grp78 elevation on western blotting of Gaucher disease
[median 60% increase compared with controls (IQR 20–100%
increase), Mann-Whitney U-test P = 0.0016], Parkinson’s disease
with GBA mutation [median 15% increase (IQR 0–50%),
P = 0.0023] and non-manifesting carrier cells [median 15%
increase (IQR 10–20%), P = 0.009]. Calnexin levels were signifi-
cantly elevated in Gaucher disease fibroblasts [median 50%
increase (IQR 50–100%), Mann-Whitney U-test P = 0.003] and
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Figure 1 Glucosylceramidase protein, activity and transcript levels. (A) Representative western blots of glucosylceramidase protein. Note
reduction in glucosylceramidase protein levels in Gaucher disease (GD) fibroblasts with a lesser degree of reduction in Parkinson’s disease
with glucocerebrosidase mutations (PD-GBA), non-manifesting carrier (NMC) and the E326K/E326K fibroblasts. (B) Bar chart summar-
izing glucosylceramidase protein levels as assessed by western blot normalized to control. Bars represent median value and 95%
confidence interval for all cell lines in each group; each line was measured on three separate blots. There are significant reductions in
Gaucher disease (Mann-Whitney U-test P5 0.001), Parkinson’s disease with glucocerebrosidase mutations (P50.001), non-manifesting
carrier (P = 0.004) and E326K/E326K lines (P = 0.003). (C) Bar chart summarizing glucosylceramidase activity levels (nmol/h/mg). Enzyme
activity was significantly reduced in fibroblasts from patients with Gaucher disease (t-test P = 0.001), patients with Parkinson’s disease
with glucocerebrosidase mutations (P = 0.004), non-manifesting carriers (P = 0.009) and E326k/E326K lines (P = 0.001) compared with
controls. Each bar represents all cell lines in each group. Results are mean  1 SD of three separate experiments done for each line.
(D) GBA transcript levels in disease lines compared to controls (n = 3), there were reduced transcript levels in GD01, GD04, GD05, and
PD03. *P50.05.
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Parkinson’s disease with GBA mutation fibroblasts [median 32%
increase (IQR 12–50%), P = 0.019].
We next measured basal oxidative stress. The rate of dihydroethi-
dium oxidation was significantly elevated in Gaucher disease,
Parkinson’s disease with GBA mutation, non-manifesting carrier and
the E326K/E326K fibroblast lines (Fig. 3A). The intensity of monochlor-
obimane staining of Gaucher disease [median 77% of control values
(IQR 50–90%), Mann-Whitney U-test P = 0.001] and Parkinson’s dis-
ease with GBA mutation fibroblasts [median 72% (IQR 50–92%) of
control, P = 0.001] was significantly less than that of control fibroblasts.
This suggests a reduction in cellular glutathione levels. Transcript levels
of the anti-oxidant NQO1 were significantly elevated in Gaucher dis-
ease [0.017 (IQR 0.014–0.019), Mann-Whitney U-test P = 0.012] and
Parkinson’s disease with GBA mutation fibroblasts [0.02 (0.016–0.023),
P = 0.024] compared with controls [0.01 (IQR 0.007–0.014)].
GBA mutations cause alterations of
lysosomal biochemistry in fibroblasts
There is no alteration in lysosomal mass in Gaucher disease or
Parkinson’s disease with GBA mutation fibroblasts; the number of
acidic vesicles (Lyso-ID), LAMP1 protein levels and beta-galactosidase
Figure 2 Evidence of endoplasmic reticulum retention of glucosylceramidase in Gaucher disease. (A) Top: immunofluorescence of control
cells showing vesicular staining of glucosylceramidase (green) at the periphery of the cell and perinuclear, reticular staining of calnexin
(red, endoplasmic reticulum marker). Bottom: co-localization of glucosylceramidase and calnexin represented by yellow perinuclear
staining with minimal green vesicular staining pattern in GD02 and GD03 cell lines. (B) Representative western blots of cell lysate treated
with endoglycosidase-H for 12 h. Note appearance of low molecular weight band in Gaucher disease samples (arrow), which represents
endoplasmic reticulum retained glucosylceramidase protein. ‘ + ’ lanes were treated with endoglycosidase-H. (C) Bar chart summarizing
percentage of endoglycosidase-H sensitive glucosylceramidase in Gaucher disease (GD) (t-test P = 0.0001), Parkinson’s disease with
glucocerebrosidase mutations (PD-GBA) (P = 0.01), non-manifesting carriers (NMC) and E326K/E326K (P = 0.001) compared with
controls. Results are mean of three experiments. (D) Top: representative western blot of BiP expression. Bottom: representative western
blot of calnexin expression. There was significant elevation of endoplasmic reticulum stress markers BiP and calnexin expression in all
Gaucher disease, Parkinson’s disease with GBA mutation and non-manifesting carrier lines.
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activity does not differ between Gaucher disease, Parkinson’s disease
with GBA mutation, non-manifesting carrier and control (Fig. 4A). On
western blotting, cathepsin D was significantly increased in Gaucher
disease [median 50% increase (IQR 32–100%), Mann-Whitney U-test
P5 0.0001] and Parkinson’s disease with GBA mutation [median 30%
increase (IQR 20–40%), P = 0.002] fibroblasts (Fig. 4D). Total beta-
hexosaminidase activity was elevated in Gaucher disease, Parkinson’s
disease with GBA mutation and non-manifesting carriers compared
with controls (Fig. 4B). Together, these data suggest secondary
changes in cathepsin D and total beta-hexosaminidase metabolism
that are not because of an overall expansion of the lysosomal
compartment.
Given the evidence of potential lysosomal dysfunction we inves-
tigated macroautophagy (Fig. 4D). Under basal conditions there
was no elevation of p62 in Gaucher disease [median 101% (IQR
90–110%) of control, Mann-Whitney U-test P = 0.9], Parkinson’s
disease with GBA mutation fibroblasts [median 100% (IQR 95–
105%) of control, P = 0.8] or non-manifesting carriers (median
99% of control, P = 0.8). Without starvation there was no alter-
ation of LC3-II in Gaucher disease (mean 82  20% of control,
P = 0.062), Parkinson’s disease with GBA mutation (mean
88  15% of control, P = 0.13) or non-manifesting carriers
(99% of control, P = 0.8). This suggests that macroautophagy is
not abnormal.
Figure 3 Oxidative stress assays in Gaucher and Parkinson’s disease fibroblasts. (A) Graph summarizing increases in rates of dihy-
droethidium oxidation rates for Gaucher disease (GD) (Mann-Whitney U-test P50.001), Parkinson’s disease with glucocerebrosidase
mutations (PD-GBA) (P50.001), non-manifesting carriers (NMC) (P50.001) and E326K/E326K (P50.001) compared with control
cells. (B) Graph demonstrating significant reduction in dihydroethidium oxidation rates for controls (n = 2), Gaucher disease (n = 3) and
Parkinson’s disease with glucocerebrosidase mutations fibroblasts (n = 2) treated with ambroxol compared to untreated cells. Results
expressed as median rate of dihydroethidium oxidation  95% confidence interval.
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Ambroxol hydrochloride improves
glucosylceramidase activity in
fibroblasts with GBA mutations by
activating the CLEAR network
Ambroxol treatment resulted in a significant elevation of glucosyl-
ceramidase protein levels in control [median increase 30% of un-
treated cells (IQR 15–40%), Mann-Whitney U-test P = 0.0085],
Gaucher disease [median increase 100% of untreated (IQR 87–
200% increase), P = 0.004], Parkinson’s disease with GBA
mutations [median increase 50% of untreated (IQR 40–130%),
P = 0.04] and non-manifesting carrier fibroblasts [median increase
35% of untreated cells (IQR 25–40% increase), P = 0.008] on
western blotting (Fig. 5). Ambroxol treatment also resulted in a
significant elevation of glucosylceramidase activity levels (Fig. 6)
and messenger RNA (Fig. 7) in Gaucher disease, Parkinson’s dis-
ease with GBA mutations and non-manifesting carriers. This was
accompanied by an almost complete abolition of the endoglyco-
sidase-H sensitive glucosylceramidase fraction (Fig. 9A) in Gaucher
disease fibroblasts. There was no evidence of cell death after
ambroxol treatment of control or Gaucher disease fibroblasts
Figure 4 Analysis of lysosomal markers and autophagy. (A) Bar chart summarizing results for LAMP1 western blot, LysoID assay and
beta-galactosidase activity. There is no significant difference in any of these variables, suggesting lysosomal mass is not altered. For each
variable results are expressed as a percentage of results from control cells (n = 3). (B) Representative western blots demonstrating
increased cathepsin D in Gaucher disease and Parkinson’s disease with GBA mutations compared to controls (top panel) and increased
LAMP1 expression after ambroxol treatment (lanes marked ‘ + ’, bottom panel). (C) Bar chart summarizing increase in total beta-hex-
osaminidase activity in Gaucher disease (GD), Parkinson’s disease with GBA mutations (PD-GBA) and non-manifesting carriers (NMC)
compared with controls. *P50.05. (D) Represenative western blots demonstrating LC3-II levels (top) and p62 (bottom). There was no
significant difference in either marker in Gaucher disease or Parkinson’s disease with GBA mutations compared to control.
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[median decrease of 15% fluorescent units (FU)/5 000 cells trea-
ted versus median decrease of 11% of FU/5 000 cells treated,
Mann-Whitney U-test P = 0.96].
To determine whether ambroxol treatment for 5 days increased
glucosylceramidase expression by activating the CLEAR network,
we performed gene expression microarray analysis of treated and
untreated control fibroblasts with a GeneChip Human Genome
U133 Plus 2.0 Array. We used control fibroblasts to avoid any
potential confounding caused by effects of GBA mutations on
lysosomal gene expression. Gene set enrichment analysis examines
how a subset of genes of interest is distributed through a set of
differentially expressed genes, by ranking genes from most upre-
gulated to most downregulated (Subramanian et al., 2005). An
enrichment score is then calculated to summarize the tendency of
the genes of interest to be upregulated (enrichment score from 0
to +1) or downregulated enrichment score from (0 to 1). Gene
set enrichment analysis demonstrated that the majority of genes
involved in lysosomal metabolism (enrichment score +0.54,
P = 0.04, false discovery rate 0.02) or autophagy (enrichment
score +0.66, P = 0.04, false discovery rate 0.022) were upregu-
lated. This result was supported by a gene set ANOVA based on
KEGG pathways demonstrated that the lysosomal pathway was
upregulated 1.21-fold in treated cells (P = 4.85  105) compared
with untreated cells. Supplementary Table 2 details the genes
involved in lysosomal function and autophagy upregulated after
ambroxol treatment.
To confirm these microarray results we examined the induction
of a subset of CLEAR genes after ambroxol treatment using quan-
titative PCR, western blotting and enzymatic assays. Transcripts
for the lysosomal proteins hexosaminidase subunit A, aspartyl glu-
cosaminidase, cathepsin K, SCARB2/LIMP2 and iduronidase alpha
all rose significantly in control, Gaucher disease and Parkinson’s
disease with GBA mutation cells after ambroxol treatment
(Supplementary Table 3). On western blotting LAMP1 levels
rose significantly in controls, Gaucher disease and Parkinson’s dis-
ease with GBA mutation after ambroxol treatment (median in-
crease 100% in each group, P50.05, Fig. 4C). Enzymatic
activity of beta-galactosidase rose significantly after ambroxol
treatment in control [median 60% increase (IQR 50–60%),
Mann-Whitney U-test P = 0.035], Gaucher disease [median 50%
increase (IQR 45–100%), P = 0.04] and Parkinson’s disease with
GBA mutation [median 70% increase (IQR 36–100%), P = 0.03].
The transcription factor TFEB activates the CLEAR network to
control lysosomal biogenesis. TFEB transcript levels rose signifi-
cantly after ambroxol treatment in control (2.25-fold increase,
Mann-Whitney U-test P = 0.02), Gaucher disease (2.5-fold
increase, P = 0.01) and Parkinson’s disease with GBA mutation
fibroblasts (1.75-fold increase, P = 0.03) (Fig. 8). TFEB strongly
induces its own expression; therefore upregulation of TFEB along
with evidence of activation of the CLEAR network strongly sug-
gests activation of TFEB transcriptional activity. To confirm this we
quantified nuclear TFEB expression using an ELISA in control
Figure 5 Ambroxol treatment significantly increases glucosyl-
ceramidase protein levels. Representative western blots showing
increased glucosylceramidase protein levels and decreased
cathepsin D levels with ambroxol treatment. ‘ + ’ represents
lanes treated with ambroxol. Ambroxol treatment resulted in a
significant elevation of glucosylceramidase protein levels in
control [median increase 30% of untreated cells (IQR 15–40%),
Mann-Whitney U-test P = 0.0085], Gaucher disease (GD)
[median increase 100% of untreated (IQR 87–200% increase),
P = 0.004], Parkinson’s disease with GBA mutations (PD-GBA)
[median increase 50% of untreated (IQR 40–130%), P = 0.04]
and non-manifesting carrier (NMC) fibroblasts [median increase
35% of untreated cells (IQR 25–40% increase), P = 0.008].
Results are derived from all cell lines in each group and represent
median value and IQR.
Figure 6 Ambroxol treatment significantly increases glucosyl-
ceramidase enzyme activity. Bar chart demonstrating significant
increase in glucosylceramidase activity (nmol/mg/h) with
ambroxol treatment in controls (t-test P = 0.001), Gaucher
disease (GD) (P = 0.0001) and Parkinson’s disease with gluco-
cerebrosidase mutations (PD-GBA) (P = 0.0001). ‘ + ’ = with
ambroxol treatment. Results are derived from all cell lines in each
group and represent the mean of three experiments  1
standard deviation.
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fibroblasts treated with ambroxol. Nuclear localization of TFEB
increased in control fibroblasts treated with ambroxol compared
to untreated cells [63% (IQR 63–65%) versus 51% (IQR 50–
52%) in untreated, Mann-Whitney U-test P = 0.046].
Ambroxol treatment improves lysoso-
mal biochemistry and oxidative stress in
fibroblasts carrying GBA mutations
In control cells cathepsin D levels did not change and beta-hex-
osaminidase activity was elevated [median 15% (IQR 5–15%),
Mann-Whitney U-test P = 0.04] after ambroxol treatment. After
ambroxol treatment cathepsin D levels fell in Gaucher disease
[median fall 30% (IQR 25–50%), P = 0.03] and Parkinson’s dis-
ease with GBA mutation cells [median fall 20% (IQR 15–40%),
P = 0.04] (Fig. 5), as did total beta-hexosaminidase activity
[Gaucher disease median fall 36.5% (IQR 26.2–50%), P = 0.012
and Parkinson’s disease with GBA mutation median fall 30% (IQR
20–50%), P = 0.019]. This suggests that ambroxol is inducing a
general increase in lysosomal mass, with improvement of gluco-
sylceramidase activity in Gaucher disease, Parkinson’s disease with
GBA mutations and non-manifesting carriers resulting in a fall in
cathepsin D and beta-hexosaminidase activity.
Ambroxol treatment significantly reduced dihydroethidium
oxidation rate in Gaucher disease [median dihydroethidium oxi-
dation rate RFU 0.05 (0.028–0.11) versus 0.027 (0.014–0.037)
with ambroxol, Mann-Whitney U-test P = 0.004], Parkinson’s dis-
ease with GBA mutation [RFU 0.06 (0.04–0.8) versus 0.03
(0.017–0.044), P = 0.001] and control [RFU 0.04 (0.024–0.06)
versus 0.026 (0.02–0.03), P = 0.028] lines (Fig. 3B).
Ambroxol treatment reduces
alpha-synuclein levels in an
overexpressing neuroblastoma line
Given the increase in glucosylceramidase activity after ambroxol
treatment, we hypothesized that this drug would reduce alpha-
synuclein levels in a cell line expressing this protein. After 5 days
of ambroxol hydrochloride treatment (60 mM) levels of HA-tagged
alpha-synuclein in the over expressing neuroblastoma cell line
decreased significantly [median fall 15% (IQR 15–25%), Mann-
Whitney U-test P = 0.034] (Fig. 9B and C). This was accompanied
by an increase in glucosylceramidase [median 30% increase (IQR
15–40%), P = 0.011] and LAMP1 protein levels [median 40% in-
crease (IQR 25–55%), P = 0.031) (Fig. 9B and C).
Discussion
Our results show that a reduction of glucosylceramidase protein
levels and activity in fibroblasts from Gaucher disease, Parkinson’s
disease with GBA mutations and non-manifesting carriers is be-
cause of a combination of decreases in GBA transcript levels and
endoplasmic reticulum retention of glucosylceramidase protein.
Fibroblasts derived from both Parkinson’s disease patients with
GBA mutations and non-manifesting carriers showed similar
changes in glucosylceramidase protein and activity levels, and
Figure 8 Ambroxol significantly increases TFEB transcript levels.
Bar chart summarizing increase (fold increase) in TFEB transcript
levels in cells treated with ambroxol, data are from two cell lines
in each group. There was a significant increase in TFEB transcript
levels for control (Mann-Whitney U-test P = 0.02), Gaucher
disease (GD) (P = 0.01) and Parkinson’s disease with glucocer-
ebrosidase mutations (PD-GBA) (P = 0.03) after treatment with
ambroxol.
Figure 7 Ambroxol treatment significantly increases glucosyl-
ceramidase transcript levels. Bar chart demonstrating significant
increase in glucosylceramidase (GCase) messenger RNA levels
after ambroxol treatment in controls (Mann-Whitney U-test,
P = 0.001), Gaucher disease (GD) (P = 0.0015) and Parkinson’s
disease with glucocerebrosidase mutations (PD-GBA)
(P = 0.001). Results are median of three experiments  95%
confidence interval.
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cellular biochemical changes. However, we had only a small
number of non-manifesting carrier fibroblast lines (from individuals
aged 60 and 82) and cannot exclude the possibility that there may
be subtle differences in glucosylceramidase metabolism and cellu-
lar biochemistry between Parkinson’s disease with GBA mutations
and non-manifesting carrier cell lines, which would only be appar-
ent in a larger cohort. Moreover, it is important to note that the
development of Parkinson’s disease in GBA mutation carriers is
age related (McNeill et al., 2012). Thus the differentiation of het-
erozygous GBA mutation cell lines into Parkinson’s disease and
non-manifesting carrier cell lines is artificial. As we cannot exclude
that the non-manifesting carriers may eventually develop
Parkinson’s disease.
Our quantitative PCR study demonstrates that the N370S and
E326K mutations do not reduce transcript levels, whereas the
recombinant alleles (RecNcil), frameshift (203insC, c1263del55)
and L444P mutations are associated with reduced GBA messenger
RNA levels. Previous studies had demonstrated normal levels of
L444P and N370S messenger RNA, with reductions of A120G and
P415R mutation bearing messenger RNA in transfected NIH 3T3
cells (Ohashi et al., 1990). GBA null mutations and the g.5255del
T mutation (predicted to cause a frameshift and stop codon) are
associated with severe reductions of GBA transcript levels (Tayebi
et al., 1998; Germain et al., 2001). The fact that we detected
reductions in GBA messenger RNA levels in cells bearing the
L444P mutation probably reflects the greater sensitivity of the
quantitative PCR technique we used, compared with the northern
blot techniques used in earlier studies. Recombinant and frame
shift mutations can cause reduced messenger RNA stability
through nonsense-mediated decay. Why transcript levels are
reduced by the L444P missense mutation is unclear. However,
missense mutations in other genes (e.g. dopamine receptor, hep-
atocyte nuclear factor 1-alpha) have been shown to be associated
with reduced transcript levels, possibly by altering messenger RNA
folding (Harries et al., 2004).
Our results also provide a framework for understanding how
GBA mutations predispose to neurodegeneration. We recently
described loss of glucosylceramidase protein and enzyme activity
in the substantia nigra of cases with Parkinson’s disease with and
without GBA mutations (Gegg et al., 2012). Several cell biology
studies demonstrate that alpha-synuclein accumulation depletes
glucosylceramidase (Mazzulli et al., 2011). Thus, the reduction in
glucosylceramidase activity and protein in heterozygous GBA mu-
tation carriers may predispose to loss of neuronal glucosylcerami-
dase activity secondary to age related alpha-synuclein
accumulation. Once this reduction in glucosylceramidase activity
crosses a hypothetical critical threshold it will result in a ‘feed-
forward’ mechanism as lysosomal dysfunction leads to alpha-
synuclein accumulation, which in turn exacerbates loss of
glucosylceramidase. As all GBA mutations are predicted (or
proven) to cause endoplasmic reticulum retention or reduced
GBA transcription/messenger RNA stability (Hruska et al., 2008)
this hypothesis explains how a wide spectrum of GBA gene mu-
tations can predispose to Parkinson’s disease. The E326K variant
has been associated with increased Parkinson’s disease risk but no
cases with Gaucher disease with a homozygous E326K genotype
have been reported (Duran et al., 2013). Here we show that the
E326K variant significantly reduces glucosylceramidase activity, al-
though to a lesser extent than other GBA mutations. This fits with
the hypothesis that E326K reduces glucosylceramidase activity suf-
ficiently to induce alpha-synuclein, but not glucosylceramide, ac-
cumulation, thus explaining its association with Parkinson’s disease
but not Gaucher disease (Duran et al., 2013). In addition, our
results demonstrate that GBA mutations are associated with evi-
dence of endoplasmic reticulum and oxidative stress in fibroblasts.
Endoplasmic reticulum and oxidative stress are well recognized as
key pathological processes in both lysosomal storage disorders and
Parkinson’s disease. Upregulation of endoplasmic reticulum stress
markers has been demonstrated in fibroblasts from patients with
GM1-gangliosidosis, neuronal ceroid lipofuscinosis and type II
Gaucher disease (Wei et al., 2008). Here we confirm that endo-
plasmic reticulum stress markers are upregulated in type I Gaucher
disease and also in Parkinson’s disease with GBA mutations,
Figure 9 Effect of ambroxol on alpha-synuclein overexpressing
neuroblastoma cell lines. (A) Representative western blots
demonstrating disappearance of endoglycosidase-H sensitive
band (arrow) in ambroxol treated Gaucher disease cell lines.
‘ + ’ = treated with ambroxol and the arrow indicates the endo-
glycosidase-H sensitive fraction. (B) Bar chart summarizing sig-
nificant increase in glucosylceramidase and LAMP1 and
significant decrease in alpha-synuclein (SNCA) after ambroxol
treatment (bars marked ‘ + ’). (C) Representative western blots
demonstrating increased LAMP1 and glucosylceramidase
(GCase) after ambroxol treatment and decreased HA-tagged
alpha-synuclein. ‘ambroxol’ = cells treated with ambroxol.
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though to a lesser degree. This is probably secondary to endoplas-
mic reticulum retention of misfolded glucosylceramidase. The rate
of dihydroethidium oxidation was significantly elevated in Gaucher
disease, Parkinson’s disease with GBA mutations, the homozygous
E326K and non-manifesting carrier fibroblasts accompanied by
depletion of glutathione levels. Similar results were reported by
Deganuto et al. (2007) in fibroblasts from patients with type II
Gaucher disease. As we detected evidence of endoplasmic reticu-
lum and oxidative stress in fibroblasts from non-manifesting
carriers it is likely that these processes contribute to the early
stages of neurodegeneration in GBA mutation carriers.
Reductions in fibroblast glucosylceramidase activity are asso-
ciated with subtle alterations in lysosomal biochemistry. There
was no alteration in lysosomal mass in Gaucher disease,
Parkinson’s disease with GBA mutation or non-manifesting carrier
fibroblasts. This is in keeping with studies of Gaucher disease bone
marrow mesenchymal cells, spleen, liver and fibroblasts (Ho et al.,
1972; Campeau et al., 2009). Nor was there evidence of impaired
macroautophagy, with no significant differences in p62 or LC3
levels. This is in keeping with studies demonstrating normal autop-
hagy in type I Gaucher disease fibroblasts (Tatti et al., 2012).
However, it must be acknowledged that we performed point
measurements of macroautophagy and did not assess autophagic
flux. Thus we cannot exclude a subtle alteration in rate of autop-
hagy. Levels of Cathepsin D protein and total-beta hexosamini-
dase activity were significantly higher in Gaucher disease and
Parkinson’s disease with GBA mutations than controls. Cathepsin
D can proteolytically activate saposin c, and so theoretically
ehance glucosylceramidase activity (Vitner et al., 2010).
Upregulation of this protein may be a homeostatic response to
glucosylceramidase loss. Upregulation of cathepsin D messenger
RNA has been described in the brain of Gaucher disease murine
models (Vitner et al., 2010), whereas in blood from patients with
Gaucher disease the activity of various cathepsins is elevated
(Moran et al., 2000). Increases in beta-hexosaminidase activity
have been reported in fibroblasts from patients with Gaucher
disease (Moffitt et al., 1978; Aureli et al., 2012). It has been
suggested that beta-hexosaminidase can catabolize other sub-
strates accumulating in Gaucher disease. These alterations in lyso-
somal biochemistry are probably compensatory responses for the
loss of glucosylceramidase activity, and could in theory impinge
upon pathways which degrade alpha-synuclein.
The finding that Parkinson’s disease with GBA mutations is
associated with reductions in glucosylceramidase activity in sub-
stantia nigra suggests that augmenting glucosylceramidase activity
may be a valid therapeutic approach to reverse the biochemical
consequences of the GBA mutation. Ambroxol hydrochloride is an
expectorant that was identified as a potential chaperone for
glucosylceramidase when it was found to protect the enzyme
from thermal denaturation (Maegawa et al., 2009). Maegawa
et al. (2009) and others, have shown that ambroxol improves
trafficking of glucosylceramidase to the lysosome and increases
glucosylceramidase activity in Gaucher disease fibroblasts
(Maegawa et al., 2009; Bendikov-Bar et al., 2013). We confirm
this and demonstrate that ambroxol also improves glucosylcerami-
dase activity and protein levels in Parkinson’s disease with GBA
mutation fibroblasts, as well as in non-manifesting carrier and
control fibroblasts. Though initially characterized as a pharmaco-
logical chaperone (Maegawa et al., 2009), our data suggest that
ambroxol can enhance glucosylceramidase activity by activating
the CLEAR network through the action of TFEB. TFEB is a tran-
scription factor that controls at least 471 genes and is the master
regulator of lysosomal biogenesis (Palmieri et al., 2011). Ambroxol
treatment led to a significant upregulation of TFEB messenger
RNA levels in all treated cells. TFEB has recently been shown to
strongly induce its own expression; therefore upregulation of TFEB
messenger RNA levels by ambroxol provides evidence that TFEB is
being activated (Settembre et al., 2013). Gene expression profiling
in ambroxol treated control cells demonstrated strong upregulation
of lysosomal and autophagy genes. This provides evidence of ac-
tivation of the CLEAR network in association with upregulation of
TFEB transcript levels. Thus ambroxol hydrochloride increases glu-
cosylceramidase activity in Gaucher disease and Parkinson’s dis-
ease with GBA mutation fibroblasts by increasing expression of
TFEB, which is associated with activation of components of the
CLEAR network (summarized in Supplementary Fig. 2). This was
accompanied by evidence of increased lysosomal enzyme protein
and activity in treated cells.
Despite a significant increase in glucosylceramidase activity after
ambroxol treatment, the activity in Gaucher disease fibroblasts
remained only a small fraction of that of control cells. However,
the reduction in cathepsin D and total beta-hexosaminidase activ-
ity after ambroxol treatment suggests improvement of lysosomal
function. Ambroxol has been used to treat patients with type I
Gaucher disease in a pilot trial, supporting the physiological rele-
vance of its effect on glucosylceramidase activity (Zimran et al.,
2012). Treatment with ambroxol also reduced the rate of dihy-
droethidium oxidation in Gaucher disease, Parkinson’s disease with
GBA mutation and control fibroblasts. Ambroxol is known to be
an anti-oxidant (Stetinova et al., 2004), explaining the reduction
in dihydroethidium oxidation rate associated with its use. Of great
importance is the demonstration that ambroxol decreases alpha-
synuclein levels in an overexpressing cell line. Lysosomes are a
major site of alpha-synuclein degradation and it is pos-
sible increased lysosomal mass results in an increased basal
alpha-synuclein degradation rate (Alvarez-Erviti et al., 2010).
Thus ambroxol hydrochloride, which can cross the blood–brain
barrier (Luan et al., 2013), can potentially target multiple pro-
cesses involved in dopaminergic neurodegeneration by improving
lysosomal function in glucosylceramidase deficient cells, by acting
as an anti-oxidant and increasing clearance of alpha-synuclein.
In summary, we demonstrate that GBA mutations predispose to
cellular glucosylceramidase deficiency by inducing endoplasmic re-
ticulum trapping of glucosylceramidase or reducing transcript
levels. Glucosylceramidase deficiency is associated with alterations
in lysosomal function and endoplasmic reticulum and oxidative
stress. Given that heterozygous mutations in the Niemann-Pick
disease gene SMPD1 have recently been associated with
Parkinson’s disease (Gan-Or et al., 2013), it is possible that similar
mechanisms explain how mutations in other autophagy-lysosome
genes increase Parkinson’s disease risk (Shachar et al., 2011).
Ambroxol hydrochloride increases glucosylceramidase activity in
control, Gaucher disease and Parkinson’s disease with GBA muta-
tion cell lines, by activating components of the CLEAR network
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through TFEB combined with chaperone activity (Supplementary
Fig. 2). The ability of ambroxol to increase glucosylceramidase in
control cells and to reduce alpha-synuclein levels in a cell model
highlights the potential benefits of manipulating the glucosylcer-
amidase pathway to lower synuclein levels in synuclein related
diseases (Schapira and Gegg, 2013).
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